Answers are grounded in this paper and cite their sources.
Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors (ICIs) have substantially improved outcomes in advanced skin malignancies. However, many patients still show resistance, experience immune-related adverse events (irAEs), or have uneven antibody penetration into tumors. Small interfering RNAs (siRNAs) provide an alternative means of targeting the same pathway by promoting RNA-induced silencing complex (RISC)-mediated degradation of PD-1/PD-L1 transcripts rather than blocking the corresponding proteins with antibodies. We propose that intratumoral siRNA could reduce PD-1/PD-L1 expression in treated tumors and alter the local immune microenvironment, while systemic ICI could extend checkpoint blockade beyond the injected lesion. We refer to this strategy as the Dual-Hit hypothesis. This article examines its mechanistic basis and summarizes the available preclinical evidence and early clinical experience, including the first-in-human study of PH-762. It also considers the delivery, intracellular, and safety-related factors that may affect clinical development. Whether this combination can improve antitumor activity over ICI alone, alter treatment requirements, or benefit patients with ICI-refractory disease remains unknown and requires clinical testing.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: